癌症中BRAF突变的分子景观与先进诊断技术:从定量PCR和ddPCR到CRISPR平台
本综述总结BRAF突变的分子异质性并批判性评估当前诊断方法,比较等位基因特异性PCR和Sanger测序与高分辨率熔解分析、微滴数字PCR和下一代测序等先进定量平台,重点分析分析灵敏度、突变覆盖度和临床适用性。文章还讨论CRISPR检测、滚环扩增系统、纳米颗粒生物传感器和即时诊断平台等新兴技术在液体活检中超灵敏检测的潜力,并审视瘤内异质性、低等位基因频率变异、FFPE相关伪影和治疗压力下克隆演化等挑战以及标准化、成本和全球可及性等临床实施障碍。
要点
- BRAF-V600E是最常见变异,组成性激活MAPK通路,影响肿瘤进展和治疗反应。
- 准确检测BRAF改变对分子分型、预后评估、治疗选择和耐药监测至关重要。
- 新兴技术如CRISPR检测和纳米颗粒生物传感器有望实现超灵敏、快速、分散化突变检测。
核心结论
- 最佳BRAF检测需要基于突变亚类的、临床整合的策略,结合全面基线分析和纵向分子监测。
- 未来诊断范式可能整合多组学数据和人工智能辅助解读,以完善精准肿瘤学实施。
研究设计与样本
- 本文为综述,总结BRAF突变的分子异质性并批判性评估当前诊断方法。
- 比较传统方法(等位基因特异性PCR和Sanger测序)与先进定量平台(高分辨率熔解分析、微滴数字PCR和下一代测序)。
- 讨论新兴技术(CRISPR检测、滚环扩增系统、纳米颗粒生物传感器和即时诊断平台)的潜力。
主要发现
- BRAF突变是多种恶性肿瘤的关键致癌改变,包括黑色素瘤、甲状腺癌、结直肠癌、非小细胞肺癌、胶质瘤和毛细胞白血病。
- BRAF-V600E诱导MAPK信号通路组成性激活,促进肿瘤进展并影响治疗反应性。
- 新兴工具在液体活检背景下具有实现超灵敏、快速和分散化突变检测的潜力。
- 关键挑战包括瘤内异质性、低等位基因频率变异、FFPE相关伪影和治疗压力下的克隆演化。
- 临床实施障碍包括标准化、成本和全球可及性。
临床怎么用
- 准确检测BRAF改变用于分子分类、预后评估、治疗选择和耐药监测。
- 考虑采用基于突变亚类的、临床整合的策略,结合全面基线分析和纵向分子监测。
- 关注新兴超灵敏检测技术在液体活检中的应用潜力。
局限性
- 瘤内异质性、低等位基因频率变异、FFPE相关伪影和治疗压力下的克隆演化构成挑战。
- 标准化、成本和全球可及性是临床实施的关键障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BRAF mutations are key oncogenic alterations across multiple malignancies, including melanoma, thyroid carcinoma, colorectal cancer, non-small cell lung cancer, glioma, and hairy cell leukemia. The most prevalent variant, BRAF-V600E, induces constitutive activation of the MAPK signaling pathway, promoting tumor progression and influencing therapeutic responsiveness. Accurate detection of BRAF alterations is therefore essential for molecular classification, prognostic assessment, treatment selection, and resistance surveillance. This review summarizes the molecular heterogeneity of BRAF mutations and critically evaluates current diagnostic methodologies. Conventional approaches such as allele-specific PCR and Sanger sequencing are compared with advanced quantitative platforms, including high-resolution melting analysis, droplet digital PCR, and next-generation sequencing, with emphasis on analytical sensitivity, mutation coverage, and clinical applicability. Emerging technologies such as CRISPR-based assays, rolling circle amplification systems, and nanoparticle-based biosensors and point-of-care diagnostic platforms are also discussed for their potential to enhance ultra-sensitive detection, particularly in liquid biopsy settings. These emerging tools are highlighted for their potential to enable ultra-sensitive, rapid, and decentralized mutation detection, particularly in liquid biopsy settings. Key challenges, including intratumoral heterogeneity, low allele-frequency variants, FFPE-associated artifacts, and clonal evolution under therapeutic pressure, are examined within a translational framework. In addition, we examine critical barriers to clinical implementation, including standardization, cost, and global accessibility of molecular diagnostics, and outline potential solutions through scalable technologies and decentralized testing strategies. We propose that optimal BRAF testing requires a mutation subclass-informed and clinically integrated strategy combining comprehensive baseline profiling with longitudinal molecular monitoring. Future diagnostic paradigms will likely integrate multi-omics data and artificial intelligence (AI)-assisted interpretation to refine precision oncology implementation. Looking forward, we propose that optimal BRAF testing will require integration of multi-omics profiling with AI-assisted interpretation, enabling automated variant classification, real-time clinical decision support, and improved prediction of therapeutic response and resistance.
引用
- Nejatinejad M, Maleki-Aram A, Namavar Abibiglou A, et al. Molecular Landscape and Advanced Diagnostic Technologies for BRAF Mutations in Cancer: From Quantitative PCR and ddPCR to CRISPR-Based Platforms. Clin Chim Acta. 2026. PMID: 42285341. doi:10.1016/j.cca.2026.121178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。